Fibroids after menopause: shrinkage, red flags and when growth means something serious

Uterine fibroids are oestrogen- and progesterone-dependent tumours. Their smooth muscle cells carry dense hormone receptors, and their growth is fuelled by the monthly hormonal cycle of the reproductive years. When ovarian oestrogen production falls at menopause, the fuel supply is cut.

Most fibroids shrink by 30–50% in the first five years after the final menstrual period. Bleeding stops with the periods, bulk symptoms often improve, and pressure on the bladder or bowel usually eases. For many women, fibroids that dominated their 40s become a non-issue in their late 50s.

Shrinkage is gradual — not overnight. A woman who reaches menopause with a 7 cm fibroid can reasonably expect it to measure 4–5 cm five years later, with corresponding improvement in symptoms.

Not every fibroid shrinks predictably. Several factors slow the process or prevent it entirely:

• Body fat produces a small amount of oestrogen (peripheral aromatisation) — higher BMI can maintain fibroids at partial size.
• Calcified fibroids — long-standing fibroids often develop calcium deposits and stay stable rather than shrinking.
• Very large fibroids (over 10 cm) may only shrink partially and can still cause bulk symptoms.
• Systemic HRT can maintain or slightly enlarge existing fibroids in a minority of women.
• Rarely, apparent lack of shrinkage or new growth signals something other than a fibroid — see red flags below.

The following symptoms in a postmenopausal woman warrant an urgent (two-week) gynaecology appointment, not a routine one:

• Any postmenopausal bleeding — even a single spot, even months or years after periods stopped.
• Any measurable growth of a known fibroid on repeat imaging.
• A new pelvic mass detected on examination or scan.
• New or worsening pelvic pain, bloating or pressure symptoms.
• Unexplained weight loss, night sweats or anaemia alongside a known fibroid.
• Rapid abdominal enlargement in a woman who has been stable for years.

Leiomyosarcoma is a rare uterine cancer that can look identical to a benign fibroid on standard ultrasound. Its incidence is roughly 1 in 500 in women having surgery for presumed fibroids, and it is more common after menopause than before. This does not mean every postmenopausal fibroid is dangerous — the vast majority remain benign — but it does mean that new growth or bleeding must be taken seriously.

Sarcoma is suspected when a fibroid grows visibly on scans after menopause, when it grows rapidly at any age (more than 2 cm in 6 months), when imaging shows atypical features (irregular borders, cystic degeneration, high vascularity, restricted diffusion on MRI), or when postmenopausal bleeding coexists with a uterine mass.

A structured work-up allows most cases to be reassured quickly and the small number of true sarcomas to be picked up early:

• Transvaginal ultrasound — first-line to characterise size, number and vascularity.
• Endometrial biopsy (pipelle) or hysteroscopy — mandatory to investigate the endometrium in any postmenopausal bleeding.
• Pelvic MRI with contrast, including diffusion-weighted imaging (DWI) and ADC mapping — the single most useful test to distinguish benign fibroid from sarcoma.
• LDH isoenzymes — sometimes used as an adjunct; raised LDH-3 can support a sarcoma diagnosis but is not sufficient alone.
• Surgical removal for definitive histology when imaging cannot fully reassure — usually total abdominal hysterectomy without morcellation.

Fear of stimulating fibroids leads many women to avoid HRT unnecessarily. In practice, systemic HRT can produce a modest re-growth of existing fibroids in a minority of women — typically 10–20% enlargement in the first 6–12 months, then stability. It rarely produces new symptoms in previously asymptomatic fibroids.

Practical points if you are considering HRT with known fibroids: transdermal oestrogen (patches, gels) has less impact on fibroid growth than oral oestrogen; combined HRT is preferred if the uterus is still present; and a baseline pelvic ultrasound before starting, then a follow-up scan at 6–12 months, provides reassurance.

Postmenopausal bleeding on HRT is never assumed to be 'just the HRT'. It requires the same urgent investigation as any other postmenopausal bleeding.

Most postmenopausal fibroids can be left alone. Treatment is reserved for specific indications:

• Any suspicion of sarcoma on imaging.
• Persistent bulk symptoms (urinary frequency, constipation, back pain) not improved by shrinkage.
• Postmenopausal bleeding with a fibroid distorting the cavity, once endometrial cancer has been excluded.
• Rapid growth or new symptoms warranting definitive tissue diagnosis.
• Very large fibroids compressing the ureters (hydronephrosis on scan).

The default operation after menopause is total abdominal or laparoscopic hysterectomy without morcellation — the safest way to remove tissue when a sarcoma cannot be entirely excluded on imaging. Preserving the uterus (myomectomy) is rarely necessary once fertility is no longer a consideration, and it carries a small risk of leaving undiagnosed sarcoma behind if morcellation is used.

Ovarian conservation is discussed individually — for many women in early menopause, keeping the ovaries has cardiovascular and bone-health benefits. For a full comparison of surgical options and recovery, see our companion guides on myomectomy vs hysterectomy and myomectomy recovery.